Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Geriatr Psychiatry Neurol ; 30(1): 50-59, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28248558

ABSTRACT

Increase in serum homocysteine is shown to be a potential risk factor for cognitive impairment. Evidence suggests that vitamin B supplementation may reduce cognitive decline by lowering the homocysteine levels. The current meta-analysis evaluated the efficacy of folic acid along with vitamin B12 and/or B6 in lowering homocysteine, thereby attenuating cognitive decline in elderly patients with Alzheimer disease or dementia. Randomized controlled trials (RCTs) comparing the efficacy of folate and B vitamin supplementation in patients with cognitive decline secondary to Alzheimer disease or dementia were identified using the keywords, "homocysteine, hyper-homocysteinemia, B vitamin, vitamin B6, B12, folic acid, cognitive, Alzheimer's disease, and dementia." The outcome measures analyzed were the Mini-Mental State Examination (MMSE) score and serum homocysteine. Of the 77 studies identified, 4 RCTs were included in the current meta-analysis. The baseline characteristics, age, and gender distribution of patients among the 2 groups (supplement vs placebo) were comparable. The results reveal that the intervention group achieved significantly greater reduction in homocysteine levels than the control (pooled difference in means = -3.625, 95% confidence interval [CI] = -5.642 to -1.608, P < .001). However, no significant difference in MMSE (pooled difference in means = 0.027, 95% CI = -0.518 to 0.573, P = 0.921) was observed between the groups. Taken together, vitamin B supplementation was effective in reducing serum homocysteine levels. However, it did not translate into cognitive improvement, indicating that the existing data on vitamin B-induced improvement in cognition by lowering homocysteine levels are conflicting.


Subject(s)
Alzheimer Disease/drug therapy , Cognition Disorders/drug therapy , Cognition/drug effects , Dementia/drug therapy , Folic Acid/therapeutic use , Homocysteine/blood , Vitamin B 12/therapeutic use , Vitamin B 6/therapeutic use , Vitamin B Complex/therapeutic use , Aged , Aged, 80 and over , Alzheimer Disease/etiology , Cognition Disorders/blood , Cognition Disorders/etiology , Dementia/etiology , Dietary Supplements , Drug Therapy, Combination , Female , Folic Acid/blood , Homocysteine/drug effects , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic , Vitamin B 12/blood , Vitamin B 6/blood , Vitamin B Complex/blood
2.
BMJ Open ; 6(11): e012175, 2016 11 15.
Article in English | MEDLINE | ID: mdl-27852711

ABSTRACT

INTRODUCTION: Whether adding percutaneous transluminal angioplasty and stenting (PTAS) to background medical treatment is effective for decreasing the incidence of stroke or death in patients with symptomatic intracranial atherosclerosis (ICAS) is still controversial. We perform a randomised controlled trial to examine the effectiveness and safety of an improved PTAS procedure for patients with ICAS. METHODS AND ANALYSIS: A randomised controlled trial will be conducted in three hospitals in China. Eligible patients with ICAS will be randomly assigned to receive medication treatment (MT) plus PTAS or MT alone. The MT will be initiated immediately after randomisation, while the PTAS will be performed when patients report relief of alarm symptoms defined as sudden weakness or numbness. All patients will be followed up at 30 days, 3 and 12 months after randomisation. The primary end point will be the incidence of stroke or death at 30 days after randomisation. Secondary outcomes will be the incidence of ischaemic stroke in the territory of stenosis arteries, the incidence of in-stent restenosis, the Chinese version of the modified Rankin Scale and the Chinese version of the Stroke-Specific Quality of Life (CSQoL). ETHICS AND DISSEMINATION: The study protocol is approved by institutional review boards in participating hospitals (reference number FZ20160003, 180PLA20160101 and 476PLA2016007). The results of this study will be disseminated to patients, physicians and policymakers through publication in a peer-reviewed journal or presentations in conferences. It is anticipated that the results of this study will improve the quality of the current PTAS procedure and guide clinical decision-making for patients with ICAS. TRIAL REGISTRATION NUMBER: NCT02689037.


Subject(s)
Angioplasty , Intracranial Arteriosclerosis/surgery , Stents , Stroke/prevention & control , Adult , Aged , China , Clinical Decision-Making , Clinical Protocols , Constriction, Pathologic/prevention & control , Female , Humans , Male , Middle Aged , Quality of Life
3.
Mol Med Rep ; 12(3): 3862-3868, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26016457

ABSTRACT

The neuroprotective agents currently used to treat Alzheimer's disease (AD) often only target one aspect of the disease process. Therefore, identifying effective drug targets associated with the pathogenesis of AD is critical for the production of novel AD therapeutic strategies. The present study aimed to investigate the underlying mechanisms of the neuroprotective effects of Rg1 on a rat model of AD. A double transgenic ß­amyloid (Aß) precursor protein/PS1 rat model was established, which co­expressed mutations associated with AD. Aß plaques and neurofibrillary tangles (NFTs) were detected by immunohistochemistry. The detection of the protein expression levels of caspase­3 and terminal deoxynucleotidyl­transferase­mediated dUTP nick end labeling (TUNEL) staining were used to determine the level of apoptosis in the brain tissue. The expression levels of the endoplasmic reticulum (ER) stress biomarker, glucose­regulated protein 78 (Grp78), and the mitochondrial apoptosis biomarkers, B­cell lymphoma 2 (Bcl­2) and Bcl­2­associated X protein (Bax), were analyzed by western blotting. Furthermore, the expression of the proteins associated with the ER stress unfolded protein response (UPR) was determined, in order to examine the levels of ER stress. The mRNA expression of downstream genes of UPR were also detected by reverse transcription­polymerase chain reaction. The protein expression levels of the apoptosis­associated phosphorylated­c­Jun N­terminal protein kinase (p­JNK), caspase­12 and cAMP response element­binding transcription factor homologous protein were determined by western blotting. The results of the present study indicated that the accumulation of NFTs and Aß plaques was significantly decreased in the Rg1­treated AD rats, compared with untreated AD rats. The expression of caspase­3 and the number of TUNEL­positive cells were also significantly decreased in the Rg1­treated rats, as compared with the AD rats. Furthermore, treatment with Rg1 significantly reduced the expression of Grp78, and triggered inositol­requiring enzyme­1 (IRE­1) and phosphorylated protein kinase RNA­like ER kinase­associated ER stress. The IRE­1 UPR pathway downstream gene, tumor necrosis factor receptor­associated factor 2, was significantly decreased in rats treated with Rg1, compared with untreated AD rats. Furthermore, the activation of p­JNK was also inhibited when AD rats were treated with Rg1. In conclusion, Rg1 was shown to function as an important factor that inhibits the accumulation of NFTs and Aß via inhibition of the ER stress­mediated pathway. Blocking of this pathway was triggered by the IRE­1 and TRAF2 pathway, as a result of inhibition of the expression of p­JNK.


Subject(s)
Alzheimer Disease/drug therapy , Apoptosis , Endoplasmic Reticulum Stress , Ginsenosides/pharmacology , Neuroprotective Agents/pharmacology , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Drug Evaluation, Preclinical , Female , JNK Mitogen-Activated Protein Kinases/metabolism , Plaque, Amyloid/drug therapy , Plaque, Amyloid/pathology , Rats, Wistar , Signal Transduction , Transcription, Genetic/drug effects , Unfolded Protein Response
4.
Pain Pract ; 15(2): 124-31, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24382126

ABSTRACT

Although triptans are widely used for treating acute migraine, they are contraindicated or not effective in a large proportion of patients. Hence, alternative treatments are needed. Calcitonin gene-related peptide receptor antagonists, such as telcagepant, have been under investigation as a treatment for acute migraine. A meta-analysis of the efficacy of telcagepant vs. placebo and triptans (zolmitriptan or rizatriptan) was performed. Randomized controlled trials were indentified from databases using the following search terms: migraine; calcitonin gene-related peptide; calcitonin gene-related peptide receptor antagonists; efficacy; safety, and telcagepant. The primary outcome measure was pain freedom 2 hours after first treatment. The secondary outcome measure was pain relief 2 hours after first treatment. Eight trials were included in the meta-analysis (telcagepant = 4011 participants). The difference in pain freedom at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.70, 95% confidence interval = 2.27-3.21, P < 0.001) and triptans over telcagepant (odds ratio = 0.68, 95% confidence interval = 0.56-0.83, P < 0.001). The difference in pain relief at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.48, 95% confidence interval = 2.18-2.81, P < 0.001). The difference in pain relief at 2 hours did not significantly favor telcagepant over triptans or vice versa (odds ratio = 0.76, 95% confidence interval = 0.57-1.01, P = 0.061). These findings indicate that telcagepant can be effective for treating acute migraine. Calcitonin gene-related peptide receptor antagonists represent a potentially important alternative means of treating acute migraine.


Subject(s)
Azepines/therapeutic use , Calcitonin Gene-Related Peptide Receptor Antagonists , Imidazoles/therapeutic use , Migraine Disorders/drug therapy , Acute Disease , Humans , Oxazolidinones/therapeutic use , Serotonin 5-HT1 Receptor Agonists/therapeutic use , Treatment Outcome , Triazoles/therapeutic use , Tryptamines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...